Back to Search
Start Over
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases.
- Source :
-
Cancer metastasis reviews [Cancer Metastasis Rev] 2024 Dec; Vol. 43 (4), pp. 1353-1371. Date of Electronic Publication: 2024 Sep 06. - Publication Year :
- 2024
-
Abstract
- MCM10 plays a vital role in genome duplication and is crucial for DNA replication initiation, elongation, and termination. It coordinates several proteins to assemble at the fork, form a functional replisome, trigger origin unwinding, and stabilize the replication bubble. MCM10 overexpression is associated with increased aggressiveness in breast, cervical, and several other cancers. Disruption of MCM10 leads to altered replication timing associated with initiation site gains and losses accompanied by genome instability. Knockdown of MCM10 affects the proliferation and migration of cancer cells, manifested by DNA damage and replication fork arrest, and has recently been shown to be associated with clinical conditions like CNKD and RCM. Loss of MCM10 function is associated with impaired telomerase activity, leading to the accumulation of abnormal replication forks and compromised telomere length. MCM10 interacts with histones, aids in nucleosome assembly, binds BRCA2 to maintain genome integrity during DNA damage, prevents lesion skipping, and inhibits PRIMPOL-mediated repriming. It also interacts with the fork reversal enzyme SMARCAL1 and inhibits fork regression. Additionally, MCM10 undergoes several post-translational modifications and contributes to transcriptional silencing by interacting with the SIR proteins. This review explores the mechanism associated with MCM10's multifaceted role in DNA replication initiation, chromatin organization, transcriptional silencing, replication stress, fork stability, telomere length maintenance, and DNA damage response. Finally, we discuss the role of MCM10 in the early detection of cancer, its prognostic significance, and its potential use in therapeutics for cancer treatment.<br />Competing Interests: Declarations Ethical approval Not applicable. Competing interests The authors declare no competing interests.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Details
- Language :
- English
- ISSN :
- 1573-7233
- Volume :
- 43
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Cancer metastasis reviews
- Publication Type :
- Academic Journal
- Accession number :
- 39240414
- Full Text :
- https://doi.org/10.1007/s10555-024-10209-3